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Vanesa Martın-Palanco, Guillermo Rodrıguez, Carmen Martın, Rafael Rojas,
Antonio Torres, Jose Roman-GomezOur group has extensively demonstrated that
hypermethylation profile of cancer-related genes
constitutes an important prognostic factor in acute
lymphoblastic leukemia (ALL) patients treated with
conventional chemotherapy [1-8]. Methylation in
this disease participates in the inactivation of 3 key
cellular pathways: (1) growth-deregulating events
comprising those that target the principal late-G1
cell–cycle checkpoint and those that regulate the G2-
M transition, (2) the apoptotic program, and (3) the
cell-cell adhesion. Moreover, methylation status is
able to redefine the prognosis of selected ALL groups
with well-established prognostic features [1-8]. In
addition, our group has recently demonstrated that
an integrated and sequential approach using ChIP-
on-chip for histone modifications, methylation, and
expression analyses makes it possible to efficiently
identify putative tumor suppressor microRNAs (miR-
NAs) specifically silenced by tumor-specific DNA
methylation in ALL cells. Our data showed that 14
miRNAs were epigenetically regulated in ALL pa-
tients. and that this methylation profile had a signifi-
cant prognostic impact [9,10].
In this sense, we have analyzed the methylation
profile of these miRNAs in a short cohort of ALL pa-
tients diagnosed from June 1990 to September 2006
at Reina Sofia Hospital. Bone marrow specimens
were obtained from all the patients at the moment
of diagnosis. High molecular weight DNA was pre-
pared from mononuclear diagnostic marrow cells
using conventional methods, frozen at 280C, andHematology Department, Reina Sofia Hospital, Maimo-
Institute for Biomedical Research (IMIBIC), Cordoba,
.
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tion profile. In all the cases, the diagnostic bone mar-
row sample contained blast cells in the ratio of at least
70%. All patients were enrolled in successive multi-
center studies of the PETHEMA study group (adult
ALL) or protocols of the SHOP study group
(childhood ALL). The purpose of our study was
to evaluate the methylation profile of these miRNAs
by methylation-specific polymerase chain reaction
(MSP) in 32 patients who received a stem cell trans-
plantation (SCT) for ALL and to determine whether
this epigenetic profile maintains its prognostic value
after this treatment that is more intensive than
conventional chemotherapy. The global rates of
methylated patients for each miRNA are shown in
Table S1 and Figure 1A. We have included 32 pa-
tients: 8 of them received an autologous-SCT and
24 an allogeneic-SCT (matched sibling donor in 17
patients, matched unrelated donor in 4, mismatched
unrelated donor in 2, and 1 patient received an allo-
SCT using an haploidentical donor). In the same
way that other studies were performed by our group,
we established 2 groups for the methylation profile:
CpG island methylator phenotype (CIMP) negative
group (CIMP2, n 5 10) that includes patients with
0-1 methylated genes and CIMP-positive group
(CIMP1, n 5 22), that includes those patients who
had more than 1 methylated gene.
As shown in Table 1, clinical and laboratory char-
acteristics were similarly distributed between the 2
groups both at diagnosis and at the transplant time.
However, patients in the CIMP2 group had a lower
relapse rate than patients in the CIMP1 group (20%
versus 64%, P 5 .05). Mortality rate was also lower
for the CIMP2 group compared with the CIMP1
group (40% versus 86%, P 5 .01).
Survival data were available on the whole cohort.
Disease-free survival (DFS) at 14 years was 78% and
20% for the CIMP2 and CIMP1 groups, respec-
tively (P 5 .033) (Figure 1B). The actuarial overall
survival (OS) at 14 years calculated for all leukemia745
Figure 1. (A) The methylation status of 14 cancer-related microRNAs was determined in pretreatment samples from 32 ALL patients undergoing
SCT. Each row represents a unique patient sample. Each column represents 1 of the 14 genes analyzed (microRNA names are listed at the top of the
figure). Methylation is shown in 2 scales: red, methylated genes; green, unmethylated genes. CIMP-negative (patients with 0 or 1 methylated genes);
CIMP-positive (patients with more than 1 methylated gene). (B) DFS curves for all the patients enrolled in this study according to the methylation
profile. CIMP2 (patients with 0-1 methylated genes); CIMP1 (patients with more than 1 methylated gene). (C) OS curves for all the patients en-
rolled in this study according to the methylation profile. CIMP2 (patients with 0-1 methylated genes); CIMP1 (patients with more than 1 methylated
gene).
746 Biol Blood Marrow Transplant 17:745-748, 2011V. Martın-Palanco et al.patients was 60% for CIMP2 patients and 6%
for CIMP1 patients (P 5 .04) (Figure 1C). The
multivariate analysis of potential prognostic factors
demonstrated that the methylation profile was an in-
dependent prognostic factor for DFS (P 5 .05) and
OS (P 5 .05) (Table S2). The methylation profile
mantains its prognostic significance for DFS when
only the allogeneic SCT group was considered
(Table S2, the low number of autologous SCT pa-
tients precluded a separate and suitable statistical
analysis).
It is accepted that ALL patients who are classi-
fied into a high-risk prognostic group should receive
a consolidation treatment with SCT, but this recom-
mendation is not so clear for other risk groups.
Recent studies have shown the benefit of this consol-
idation treatment in standard-risk patients, whereas
the improvement, in terms of DSF, in a high-risk
group can have been overestimated [11]. Allogeneic
SCT may be the only curative antileukemic therapy,
but the high transplant-related mortality can explainwhy the selection of patients for this procedure
remains a debated issue. Further improvement in
outcome and reduction in toxicity will require the
identification and application of new prognostic
factors and novel treatment strategies. In this sense,
we have shown that methylation status of several
miRNAs is a good predictor of ALL outcome
after SCT and suggests that epigenetic biomarkers
could improve the stratification of patients into risk
groups. Interestingly, we have recently demonstrated
that the epigenetic regulation of the hsa-miR-124a
(one of the microRNA families most frequently
methylated in our patients) mediates, at least in
part, the increased expression of CDK6 and contrib-
utes to the abnormal proliferation of ALL cells both
in vitro and in vivo [10]. All these findings openup
the possibility of new therapeutic strategies for these
patients either targeting epigenetically regulated
miRNAs using drugs that inhibit methylation and
histone modifications and/or directly targeting the
CDK6 protein.
Table 1. Clinical Characteristics andOutcomeofALLPatients
Feature
CIMP +
(n 5 22)
CIMP –
(n 5 10) P Value
Age at diagnosis, n 1.000
<14 years 7 3
$15 years 15 7
Sex (M/F), n 12/10 8/2 .24
WBC, n .42
#50  109/L 16 5
>50  109/L 6 5
FAB classification, n .70
L1 7 4
L2 15 6
L3 0 0
Blast lineage, n .42
B cell 13 8
T cell 9 2
Cytogenetic/molecular abnormalities, n .25
BCR-ABL 6 3
t(1;19) 0 1
11q23 1 0
MYC 1 0
7q35-14q11 3 0
TEL-AML1 2 0
Normal 7 2
Others 1 2
NT 1 2
Type of transplant .21
Autologous 4 4
Allogeneic 18 6
Age at transplant, n .44
<14 years 6 2
15-29 years 8 6
30-39 years 7 1
40-49 years 1 1
Donor-recipient sex match
(only allogeneic) n 5 24
.36
Male-male 5 3
Male-female 6 0
Female-male 3 2
Female-female 3 1
Missing 1 0
Disease status prior transplant .50
First complete remission 11 7
>First complete remission 9 2
Relapse 2 1
Type of donor (only allogeneic) n 5 24 .29
HLA-identical sibling 13 4
Unrelated well matched 3 1
Unrelated mismatched 2 0
Haploidentical donor 0 1
Graft type .18
Cord blood 2 0
Bone marrow 3 4
Peripheral blood 17 6
Conditioning regimen .62
Cyclophosphamide + TBI 16 7
Cyclophosphamide + Others 4 1
Other 2 2
GVHD prophylaxis (only allogeneic)
n 5 24
.18
T cell depletion (ATG) 0 1
CSA + MTX 12 4
Others 6 1
Acute GVHD (only allogeneic) n 5 24 .15
0-I 5 4
II- IV 13 2
Chronic GVHD (only allogeneic)
n 5 24
6 2 1.00
Relapse, n 14 2 .05
Death, n 19 4 .01
(Continued )
Table 1. (Continued )
Feature
CIMP +
(n 5 22)
CIMP –
(n 5 10) P Value
Main causes of death .46
Relapse 10 1
Infectious disease 6 1
GVHD 1 1
Others 2 1
ALL indicates acute lymphoblastic leukemia; GVHD, graft-versus-host
disease; ATG, antithymocyte globulin; WBC, white blood cell; TBI,
total-body irridiation; CSA, cyclosporine; MTX, methotrexate.
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